Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CG-LR1
- Development stage
- Preclinical
- Lead developer
- Lerna Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CG-LR1 is a first-in-class GalNAc-conjugated small interfering RNA (siRNA) therapeutic being developed by Lerna Biopharma (formerly Cargene Therapeutics) for the treatment of chronic liver diseases, including liver cirrhosis and liver fibrosis. Discovered through the proprietary Quartz target discovery platform, CG-LR1 targets integrin alpha FG-GAP repeat containing 1 (ITFG1). By utilizing RNA interference to reduce ITFG1 expression, the drug aims to leverage the liver's innate regenerative capacity, potentially sustaining or improving liver function and offering an alternative to liver transplantation. It is currently in preclinical development and is designed for targeted delivery to hepatocytes.
02
Targets
ITFG1 (Integrin alpha FG-GAP repeat containing 1)
Beyond the preview
Go deeper on CG-LR1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CG-LR1.